Literature DB >> 3149044

Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.

K Huber1, D Rosc, I Resch, E Schuster, D H Glogar, F Kaindl, B R Binder.   

Abstract

A decrease in the fibrinolytic potential, mainly due to an elevation of plasminogen activator inhibitor (PAI), has been described in patients with stable coronary artery disease and a previous myocardial infarction. We investigated plasma levels of PAI and tissue plasminogen activator (t-PA) and their possible circadian variations in patients with unstable coronary artery disease (CAD). Sixty-three patients were studied for at least 2 consecutive days during their stay at the coronary care unit (CCU). Diurnal plasma fluctuations in PAI and t-PA and onset of further myocardial ischemic episodes were monitored. As controls we used 22 age-matched patients submitted to the clinic because of non cardiac chest pain or valvular disease who revealed no evidence of CAD. PAI levels were significantly elevated in patients with unstable CAD (p less than 0.0001) but were not influenced by the extent of underlying CAD, history of previous myocardial infarction, known risk factors for CAD, or by extent of myocardial damage. The circadian variation of PAI levels with peak values between midnight and 6 A.M. found in controls was still present in patients but at a higher level. Preservation of circadian pattern in PAI plasma levels despite myocardial ischemic attacks indicates that elevation of PAI is rather not caused by a reactive phenomenon. On the other hand, elevated PAI levels and episodes of severe myocardial ischemia exhibiting a median time of onset at 10 A.M. seem to be closely related.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149044

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.

Authors:  Seema A Kothari; Mytrang K Le; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 2.  Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 3.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

4.  Effect of a Change in the Sleep/Wake Cycle on the Diurnal Variation of Fibrinolytic Parameters.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

5.  Circadian patterns of ST elevation myocardial infarction in the new millennium.

Authors:  Rajan Kanth; Sunitha Ittaman; Shereif Rezkalla
Journal:  Clin Med Res       Date:  2013-04-11

6.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03

7.  Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.

Authors:  A B Bridges; M McLaren; N A Scott; T H Pringle; G P McNeill; J J Belch
Journal:  Br Heart J       Date:  1993-02

Review 8.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.

Authors:  I Juhan-Vague; M C Alessi; P Vague
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

9.  [Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct].

Authors:  C Baumgartner; K Huber; F Holzner; K Zeiler; E Auff; B R Binder
Journal:  Klin Wochenschr       Date:  1988-11-15

10.  Dietary fat differentially influences the lipids storage on the adipose tissue in metabolic syndrome patients.

Authors:  Antonio Camargo; Maria E Meneses; Pablo Perez-Martinez; Javier Delgado-Lista; Yolanda Jimenez-Gomez; Cristina Cruz-Teno; Francisco J Tinahones; Juan A Paniagua; Francisco Perez-Jimenez; Helen M Roche; Maria M Malagon; Jose Lopez-Miranda
Journal:  Eur J Nutr       Date:  2013-08-07       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.